The FDA's extension of its BLA Priority Review for lifileucel, a product of Iovance Therapeutics, is a positive development for the company. This has led to an increase in the company's stock price as it indicates the FDA's continued interest and potential approval of the product. However, the extension is due to resource constraints, which may imply a delay in the final decision.